Oaktree Acquisition Corp. III Life Sciences, a blank check company focused on mergers and acquisitions in the life sciences sector, has released its Form 10-Q report for the quarter ended September 30, 2025. The report provides a detailed overview of the company's financial performance and operational activities during the period.
Financial Highlights
Net Income: The company reported a net income of $1.97 million for the three months ended September 30, 2025. This was primarily driven by interest earned on cash held in the trust account amounting to $2.19 million, offset by general and administrative expenses of $225,579.
Net Income: For the nine months ended September 30, 2025, the company achieved a net income of $5.50 million, mainly due to interest earned on cash held in the trust account totaling $6.44 million, offset by general and administrative expenses of $940,191.
Net Income Per Share, Class A ordinary shares: $0.08 for the three months ended September 30, 2025.
Net Income Per Share, Class A ordinary shares: $0.22 for the nine months ended September 30, 2025.
Net Income Per Share, non-redeemable Class A and B ordinary shares: $0.08 for the three months ended September 30, 2025.
Net Income Per Share, non-redeemable Class A and B ordinary shares: $0.22 for the nine months ended September 30, 2025.
Business Highlights
Company Overview: Oaktree Acquisition Corp. III Life Sciences is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
Operational Activities: The company has not commenced any operations and has not generated any operating revenues. Its activities have been limited to organizational tasks, preparing for the initial public offering, and identifying a target company for a business combination.
Interest Income: The company generates non-operating income in the form of interest income on marketable securities held in the trust account.
General and Administrative Expenses: The company incurs expenses related to being a public company, including legal, financial reporting, accounting, and auditing compliance, as well as due diligence expenses in connection with completing a business combination.
Recent Developments: On October 17, 2025, David A. Berry, MD, PhD, was appointed as an independent director of the company. On October 29, 2025, Thomas Sweeney resigned as Chief Financial Officer, and George A. Martinez was appointed as the new CFO.
Future Outlook: The company expects to continue incurring significant costs in pursuit of its acquisition plans and cannot assure the successful completion of a business combination. The company has until October 25, 2026, to consummate a business combination, with the possibility of extending the period subject to shareholder approval.
Liquidity and Capital Resources: As of September 30, 2025, the company had cash of $199,769,089 held in the trust account and $1,328,841 outside the trust account. The funds outside the trust account are intended for identifying and evaluating target businesses and completing a business combination.
Going Concern Considerations: The company may need to raise additional capital through loans or investments from its sponsor, shareholders, officers, directors, or third parties to meet its working capital needs. There is substantial doubt about the company's ability to continue as a going concern if a business combination is not completed within the specified period.
SEC Filing: